Webinars

During this webinar, Philipp Rosenbaum, Senior Healthcare Analyst for Infectious Diseases & Michael Breen, Director for Infectious Diseases will summarize the vaccine rollout and future considerations.

The webinar will last approximately 45 minutes and will help you to:
Learn how different countries approached addressing COVID-19 via vaccination
Understand which vaccines were implemented in each region and why
Probe which factors made rollouts more or less successful
Analyze the impact the rollouts have had on rates of disease and transmission
Discuss future implications of the rollouts and returns to normalcy

"Charles will discuss our views for next year and consider some of the important questions to ask
Did the 2020 recession end the cycle, or just interrupt it?
Has the vaccine cut the risk of scarring globally? "

China is a major active pharmaceutical ingredient (API) and intermediate manufacturer for the global drug industry, with many countries like the US heavily reliant on its API. Join Fiona Barry, Editor of PharmSource of PharmSource, as she explores some of the major trends shaping the Chinese pharmaceutical market today, including manufacturing, COVID-19 vaccine development, and a shift towards innovation.

The webinar will last approximately 60 minutes and will cover:
An overview of China's strong small molecule API manufacturing
China's leading position in COVID-19 vaccine development
Licensing deals involving novel drugs from foreign companies
How China leads in the generation of real-world evidence in clinical trials

"Dario Perkins and Christopher Granville discuss the prospects for returning to pre-COVID “normality”. They look at the nature of the COVID downturn (the notorious “K”) and whether the vaccine can provide the silver bullet that means we can escape from this crisis with minimal long-term scarring.

They also explore the prospects for secular stagnation. Has the pandemic made the secular growth story even bleaker, or could we break out of this funk into a new “roaring 20s”? They argue it would brave to assume a secular reflation story, especially as there is no guarantee fiscal policymakers have fully understood the lessons of the last decade (unlike central bankers…)"

COVID-19: Where Are We Right Now, and What Is the State of Vaccine Development?

COVID-19 Therapeutics: Why Therapies Will Continue to Be Critical Even After the Launch of a Vaccine

Almost two years on from the first identified cases of the novel coronavirus, the effects of the pandemic are continuing to make themselves felt on the medical devices market. Countries around the world are still battling new waves and surges, even as vaccine rollout carries on apace.

Join Product Manager, Alison Casey, Data Scientist Kamilla Kan, and Senior Analyst Dominic Tong as they guide you through the shifts in medical device sales stemming from the coronavirus pandemic.

This 45-minute webinar will cover:
The impact of COVID-19 on medical device sales
Recovery trends of key medical device markets in response to COVID-19
Measuring the recovery of semi-urgent and elective medical device sales

Dario Perkins explained how the consensus Goldilocks scenario was less certain that all of the consensus was assuming. On the downside, a lot was still unknown about vaccine efficacy and any problems could postpone the recovery. But given huge pent-up demand, the revival in the global economy could also prove more potent – turning the reflation trade into an outright inflation scare. Central banks would lean against any turbulence in markets, but they might also try to exit their QE programmes. The global financial system was extremely sensitive to borrowing costs. Finally, Dario analysed the medium-term outlook for fiscal policy, which could have a huge bearing on both the macro environment and market risks over the next few years.

"Vaccine deployment less important for China than other major economies...
...but the soft-power potential of Chinese vaccines opens a new ‘global fractures’ front
That assumes the efficacy of one or more Chinese vaccine candidates [peg for substantive review]
Beijing has signalled easing up on BRI: are vaccines any kind of substitute, presaging a new strategy?
How do vaccines, and the wider pandemic aftermath, play into China’s overall external strategy in areas like Asia trade (RCEP), SCO/BRICS, and the “second leg” of the Dual Circulation? "

"Brazil finally started national Covid-19 vaccine distribution last week, but there are mounting concerns that supplies will be limited.
Bolsonaro’s administration is largely to blame for Brazil's failure to secure adequate doses of the vaccine.
Amid rising economic uncertainty and a strong second wave of Covid-19 infections, the Bolsonaro government has seen its approval rating plummet in recent weeks…
…and the end of the emergency aid payments will further pressure his approval, increasing the risk of populist economic policies.
Although impeachment is still not our base-case, calls for Bolsonaro’s removal from office have increased in recent weeks and are likely to continue, especially if the economic recovery falters. "

Join a distinguished panel of GlobalData’s foremost experts for insight into the shape of the post-pandemic recovery. They’ll be discussing the future of work as well as the impact of COVID-19 on the pharmaceutical industry, medical markets, and the consumer landscape.

The webinar will last approximately 45 minutes and will cover:
• What will office life look like? How should businesses support staff in the new hybrid world?
• Technologies that have witnessed the greatest adoption during the pandemic and what this means for the future
• Vaccine distribution worldwide and herd immunity
• Recovery trends in key medical device markets in response to COVID-19
• Key consumer trends in the wake of COVID-19

"A virulent second wave, new virus mutations, and the poor vaccine rollout postpone EA recovery. Risks of scarring are on the rise.
Mario Draghi could be good news for Italy, but he is no silver bullet for the country's structural deficiencies
Don’t be fooled by the recent upward surprises in inflationary pressures. The underlying trend is firmly disinflationary"